Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Who’s Hired? Alvotech Brings In New Quality Chief

As Lupin Appoints A CSO From Hikma, Which Sees Multiple Executives Move On

Executive Summary

Alvotech has appointed a new chief quality officer in the wake of manufacturing deficiencies being identified by the US FDA. Meanwhile, multiple executives have departed from Hikma’s management team, with one joining Lupin as chief scientific officer.

You may also be interested in...



Who’s Hired? Alvotech Names New COO After Refiling Adalimumab

Alvotech has appointed a fresh chief operating officer as it continues to pursue a US approval for its adalimumab biosimilar. Meanwhile, Strides Pharma Science’s strategy head has left the company and Nick Haggar has joined Biocon’s board, while US association the AAM has also welcomed new staff.

After Latest Adalimumab CRL, Alvotech Gets Another New Quality Chief

Six months after replacing its chief quality officer, biosimilars specialist Alvotech has again appointed a new head of quality, in the wake of the latest US FDA knockback for its AVT02 proposed adalimumab biosimilar rival to Humira.

Alvotech Switches CEO And Takes COO From Teva

Major leadership changes are being made at the top of Alvotech, with founder Robert Wessman stepping in to replace Mark Levick as CEO at the same time as Teva’s former head of global R&D, Hafrun Fridriksdottir, becomes COO of the biosimilars developer.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

GB152224

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel